BioNTech (BNTX) CEO Ugur Sahin Sells 49,000 Shares

What Happened

• Ugur Sahin, CEO of BioNTech SE, reported sales of a total 49,000 ordinary shares in two transactions. On 2026-09-15 he sold 34,000 shares at $96.49 each for $3,280,636, and on 2026-09-16 he sold 15,000 shares at $96.09 each for $1,441,340—total proceeds ≈ $4,721,976.
• These were sales (not purchases); sales are often routine but do reduce insider shareholdings.

Key Details

• Transaction dates and prices:
  • 2026-09-15: 34,000 shares @ $96.49 — $3,280,636.
  • 2026-09-16: 15,000 shares @ $96.09 — $1,441,340.
• Reported as open‑market/private sales (Form 4 sale code “S”).
• Shares owned after transaction: not specified in the excerpted filing; the Form 4 notes beneficial ownership via Medine GmbH (see footnote).
• Footnote (F1): The ordinary shares are held by Medine GmbH, of which Sahin is the sole shareholder. 106,721 shares noted are held in trust for an individual; Medine exercises voting (but not dispositive) power over those trust shares. Sahin may be deemed to beneficially own the shares held by Medine GmbH.
• The filing states the sales were effected pursuant to a Rule 10b5‑1 trading plan established by Sahin on June 3, 2026.
• Timeliness: Form filed 2026-09-16 covering a 2026-09-15 transaction and a 2026-09-16 transaction; the filing appears to have been made promptly (not marked late).

Context

• The trades were executed under a pre-established Rule 10b5‑1 plan, which specifies pre-set instructions and is commonly used to avoid questions about timing; this planning is disclosed in the filing.
• Sales reduce an insider’s stake but, by themselves, do not indicate management’s longer-term view—retail investors should consider these trades alongside other company news and fundamentals.